Ascendis Pharma (ASND) Tops Q2 EPS by EUR 37c, Beats on Revenue; Offers FY23 Revenue Guidance

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR2.16), EUR0.37 better than the analyst estimate of (EUR2.53). Revenue for the quarter came in at EUR47.4 million versus the consensus estimate of EUR37.37 million.

GUIDANCE:

Ascendis Pharma sees FY2023 revenue of EUR150-160 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations